Using a triple-biomarker scheme to evaluate Alzheimer’s disease pathology in memory clinic attendees

Takeaway

  • The ATN (amyloid, tau and neurodegeneration) biomarker categorization system can be used to evaluate pathology, although may need adapting for routine clinical use.

Why this matters

    The ATN system was developed in a research setting, but how it performs in a clinical setting is unclear. It could be a useful system to aid clinical diagnosis along the Alzheimer’s disease continuum.